Ratiopharm Canada Inc., part of the privately-owned Merckle group of companies headquartered in Ulm, Germany, announced on May 30, 2000, the acquisition of Technilab Pharma Inc., Canada’s third largest generic drug manufacturer and distributor. The purchase price was in excess of $80 million.
Heenan Blaikie acted for Ratiopharm with a team that included, from the Montreal office, Auguste Masson and Etienne Dubreuil (corporate/commercial), Eric Levy and Neil Wiener (securities), André P. Gauthier and Manon Thivierge (tax) and Subrata Bhattacharjee of the firm’s Toronto office (competition). Technilab was represented by the Montreal office of Fraser Milner Casgrain. The Fraser Milner Casgrain team included Claude Leduc and Charles R. Spector. Acting for the Sabourin Family, the controlling shareholders of Technilab, was Serge Bourque from the Montreal office of Lavery, de Billy. Acting for the independent committee of the Board of Directors of Technilab was Paul Raymond from the Montreal office of Ogilvy Renault.